April 25, 2018 / 11:17 AM / a month ago

BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study

April 25 (Reuters) - Zynerba Pharmaceuticals Inc:

* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2

* ZYNERBA PHARMACEUTICALS - LOOK FORWARD TO INITIATING A PHASE 2B STUDY IN ADULT REFRACTORY FOCAL SEIZURES IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below